Cell>Point enters deal for commercialization of imaging agents

03/14/2013 | Business Wire

Cell>Point said it has secured a licensing deal with South Korean firm Hanmi Pharmaceutical. The agreement involves the development and commercialization of Cell>Point's cancer and cardiology imaging agent, to be developed through its ethylenedicysteine-glucosamine technology. The partnership will initially produce technetium-99m-labeled EC-G for SPECT and SPECT/CT uses. The collaboration will cover gallium-68-labeled EC-G for PET/CT imaging later on.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI